Fleischhacker, Walter

Publications

Sort by

Co-Author Network

selected publications

Impact of Long-Acting Injectable Versus Oral Antipsychotic Treatment on All-Cause Discontinuation Risk in People with Early Phase Schizophrenia and Comorbid Substance Use Disorder: A Secondary Analysis of the EULAST Randomized Trial. CNS drugs. 2025 Academic Article GET IT
Subjective well-being in early-phase schizophrenia patients using long-acting injectable vs. oral antipsychotic drugs: data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST). European psychiatry : the journal of the Association of European Psychiatrists. 2025 Academic Article GET IT
AI-based prediction of depression symptomatology in first-episode psychosis patients: insights from the EUFEST and RAISE-ETP clinical trials. Psychological medicine. 2025 Academic Article GET IT
Multivariable prediction of functional outcome after first-episode psychosis: a crossover validation approach in EUFEST and PSYSCAN. Schizophrenia (Heidelberg, Germany). 2024 Academic Article GET IT
Clinical symptoms and psychosocial functioning in patients with schizophrenia spectrum disorders testing seropositive for anti-NMDAR antibodies: a case-control comparison with patients testing negative. The lancet. Psychiatry. 2024 Academic Article GET IT
Times cited: 4
Relapse in clinically stable adult patients with schizophrenia or schizoaffective disorder: evidence-based criteria derived by equipercentile linking and diagnostic test accuracy meta-analysis. The lancet. Psychiatry. 2023 Review GET IT
Times cited: 9
Cannabis Use and Symptomatic Relapse in First Episode Schizophrenia: Trigger or Consequence? Data From the OPTIMISE Study. Schizophrenia bulletin. 2023 Academic Article GET IT
Times cited: 11
The use of long-acting injectables in early-phase schizophrenia - Authors' reply. The lancet. Psychiatry. 2023 Letter GET IT
Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST). The lancet. Psychiatry. 2023 Academic Article GET IT
Times cited: 30
Multinational perspectives on changes to psychiatric care during the COVID-19 pandemic: a survey of practicing psychiatrists. Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater. 2023 Academic Article GET IT
The transition from adolescence to adulthood in patients with schizophrenia: Challenges, opportunities and recommendations. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2022 Review GET IT
Times cited: 17
Scalability of the Positive and Negative Syndrome Scale in first-episode schizophrenia assessed by Rasch models. Acta psychiatrica Scandinavica. 2022 Academic Article GET IT
Times cited: 10
European Validation of the Self-Evaluation of Negative Symptoms (SNS): A Large Multinational and Multicenter Study. Frontiers in psychiatry. 2022 Academic Article GET IT
Times cited: 18
Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. The lancet. Psychiatry. 2021 Academic Article GET IT
Times cited: 108
Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial. The lancet. Psychiatry. 2020 Academic Article GET IT
Times cited: 51
Corrigendum to "Changes in psychopathology in schizophrenia patients starting treatment with new-generation antipsychotics: therapeutic drug monitoring in a naturalistic treatment setting" [Eur. Neuropsychopharmacol. 26 (2016) 717-728]. 2020 GET IT
Times cited: 2
A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2019 Academic Article GET IT
Times cited: 68
Correction: Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study. 2019 GET IT
Times cited: 1
The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors. European psychiatry : the journal of the Association of European Psychiatrists. 2019 Academic Article GET IT
Times cited: 98
Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study. Translational psychiatry. 2019 Academic Article GET IT
Times cited: 59
Self-stigma versus stigma resistance in schizophrenia: Associations with resilience, premorbid adjustment, and clinical symptoms. Psychiatry research. 2018 Academic Article GET IT
Times cited: 40
Early Placebo Improvement Is a Marker for Subsequent Placebo Response in Long-Acting Injectable Antipsychotic Trials for Schizophrenia: Combined Analysis of 4 RCTs. The Journal of clinical psychiatry. 2018 Review GET IT
Times cited: 4
Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2018 Academic Article GET IT
Times cited: 45
Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis. The American journal of psychiatry. 2018 Academic Article GET IT
Times cited: 129
Placebo effects in adult and adolescent patients with schizophrenia: combined analysis of nine RCTs. Acta psychiatrica Scandinavica. 2018 Academic Article GET IT
Times cited: 7
Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. The lancet. Psychiatry. 2018 Academic Article GET IT
Times cited: 163
Characteristics of Involuntarily Admitted Patients and Treatment Patterns Over a 21-Year Observation Period. Journal of clinical psychopharmacology. 2018 Academic Article GET IT
Trends in pharmacological emergency treatment of patients suffering from schizophrenia over a 16-year observation period. International clinical psychopharmacology. 2018 Academic Article GET IT
Times cited: 4
Relapse After Antipsychotic Discontinuation in Schizophrenia as a Withdrawal Phenomenon vs Illness Recurrence: A Post Hoc Analysis of a Randomized Placebo-Controlled Study. The Journal of clinical psychiatry. 2018 Academic Article GET IT
Times cited: 23
The long-term treatment of schizophrenia with antipsychotics: a perennial debate. World psychiatry : official journal of the World Psychiatric Association (WPA). 2018 Academic Article GET IT
Times cited: 5
Quality of life in stabilized outpatients with bipolar I disorder: Associations with resilience, internalized stigma, and residual symptoms. Journal of affective disorders. 2018 Academic Article GET IT
Times cited: 48
Baseline results from the European non-interventional Antipsychotic Long acTing injection in schizOphrenia (ALTO) study. European psychiatry : the journal of the Association of European Psychiatrists. 2018 Academic Article GET IT
Times cited: 20
Religiosity and psychological resilience in patients with schizophrenia and bipolar disorder: an international cross-sectional study. Acta psychiatrica Scandinavica. 2017 Academic Article GET IT
Times cited: 34
Impact of Social Cognition on Alcohol Dependence Treatment Outcome: Poorer Facial Emotion Recognition Predicts Relapse/Dropout. Alcoholism, clinical and experimental research. 2017 Academic Article GET IT
Times cited: 69
Why do indiviuals with schizophrenia drop out of observational clinical trials?. Psychiatry research. 2017 Academic Article GET IT
Times cited: 10
A Meta View on Meta-analyses. JAMA psychiatry. 2017 Comment GET IT
Times cited: 8
Executive Dysfunctions Predict Self-Restricted Driving Habits in Elderly People with or without Alzheimer's Dementia. Pharmacopsychiatry. 2017 Academic Article GET IT
Times cited: 11
[Burnout in physicians]. Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater. 2017 Academic Article GET IT
Times cited: 6
The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia. The American journal of psychiatry. 2017 Review GET IT
Times cited: 166
Schizophrenia and substance abuse: Is schizophrenia forgotten?. Current opinion in psychiatry. 2017 Editorial Article GET IT
Times cited: 2
Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet (London, England). 2017 Academic Article GET IT
Times cited: 286
Naming for Psychotropic Drugs: Dilemma and Challenge. Pharmacopsychiatry. 2017 Academic Article GET IT
Times cited: 8
Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study. The international journal of neuropsychopharmacology. 2017 Academic Article GET IT
Times cited: 79
Severity of Depression Impacts Imminent Conversion from Mild Cognitive Impairment to Alzheimer's Disease. Journal of Alzheimer's disease : JAD. 2017 Academic Article GET IT
Times cited: 23
Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase III FlashLyte and DayLyte Studies. Biological psychiatry. 2016 Academic Article GET IT
Times cited: 113
Prescribing Practice in Inpatients Versus Outpatients With Schizophrenia Initiating Treatment With Second-Generation Antipsychotics: A Naturalistic Follow-Up Study. Journal of clinical psychopharmacology. 2016 Academic Article GET IT
Times cited: 5
Emotional intelligence and non-social cognition in schizophrenia and bipolar I disorder. Psychological medicine. 2016 Academic Article GET IT
Times cited: 18
Placebo controls in clinical trials: concerns about use in relapse prevention studies in schizophrenia. BMJ (Clinical research ed.). 2016 Academic Article GET IT
Times cited: 7
[Antipsychotic-induced tardive syndromes]. Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater. 2016 Review GET IT
Times cited: 7
Multisite prediction of 4-week and 52-week treatment outcomes in patients with first-episode psychosis: a machine learning approach. The lancet. Psychiatry. 2016 Academic Article GET IT
Times cited: 162
Quality of life in stabilized patients with schizophrenia is mainly associated with resilience and self-esteem. Acta psychiatrica Scandinavica. 2016 Academic Article GET IT
Times cited: 65
Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. Schizophrenia research. 2016 Academic Article GET IT
Times cited: 90
Psychotic disorders in DSM-5 and ICD-11. CNS spectrums. 2016 Review GET IT
Times cited: 79
The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial: Rationale for Its Methodology and a Review of the Effectiveness of Switching Antipsychotics. Focus (American Psychiatric Publishing). 2016 Academic Article GET IT
The usefulness of rating scales in patients with schizophrenia. Acta psychiatrica Scandinavica. 2016 Editorial Article GET IT
Times cited: 4
Clinical and biological correlates of resilience in patients with schizophrenia and bipolar disorder: A cross-sectional study. Schizophrenia research. 2016 Academic Article GET IT
Times cited: 58
How precise is precision medicine for schizophrenia?. Current opinion in psychiatry. 2016 Editorial Article GET IT
Times cited: 8
Bilirubin concentration correlates with positive symptoms in patients with schizophrenia. The Journal of clinical psychiatry. 2016 Academic Article GET IT
Times cited: 12
Predictors of discontinuation of antipsychotic medication and subsequent outcomes in the European First Episode Schizophrenia Trial (EUFEST). Schizophrenia research. 2016 Academic Article GET IT
Times cited: 27
Changes in psychopathology in schizophrenia patients starting treatment with new-generation antipsychotics: therapeutic drug monitoring in a naturalistic treatment setting. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2016 Academic Article GET IT
Times cited: 4
Resilience, internalized stigma, self-esteem, and hopelessness among people with schizophrenia: Cultural comparison in Austria and Japan. Schizophrenia research. 2016 Academic Article GET IT
Times cited: 76
Impulsivity and Alcohol Dependence Treatment Completion: Is There a Neurocognitive Risk Factor at Treatment Entry?. Alcoholism, clinical and experimental research. 2015 Academic Article GET IT
Times cited: 57
Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies. European psychiatry : the journal of the Association of European Psychiatrists. 2015 Academic Article GET IT
Times cited: 24
Relating Spontaneously Reported Extrapyramidal Adverse Events to Movement Disorder Rating Scales. The international journal of neuropsychopharmacology. 2015 Academic Article GET IT
Times cited: 1
Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia. Schizophrenia bulletin. 2015 Academic Article GET IT
Times cited: 86
Use of Benzodiazepines in Alzheimer's Disease: A Systematic Review of Literature. The international journal of neuropsychopharmacology. 2015 Academic Article GET IT
Times cited: 90
Schizophrenia: when clozapine fails. Current opinion in psychiatry. 2015 Review GET IT
Times cited: 26
The problem of substance abuse in people with schizophrenia. Current opinion in psychiatry. 2015 Editorial Article GET IT
Times cited: 1
Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2015 Review GET IT
Times cited: 95
Differential effects of antipsychotic drugs on insight in first episode schizophrenia: Data from the European First-Episode Schizophrenia Trial (EUFEST). European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2015 Academic Article GET IT
Times cited: 31
The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics. Schizophrenia bulletin. 2015 Review GET IT
Times cited: 46
The promise of biological markers for treatment response in first-episode psychosis: a systematic review. Schizophrenia bulletin. 2015 Academic Article GET IT
Times cited: 77
Modeling determinants of medication attitudes and poor adherence in early nonaffective psychosis: implications for intervention. Schizophrenia bulletin. 2015 Academic Article GET IT
Times cited: 38
Patient-Centered Outcomes with Aripiprazole Once-Monthly for Maintenance Treatment in Patients with Schizophrenia: Results From Two Multicenter, Randomized, Double-Blind Studies. Clinical schizophrenia & related psychoses. 2015 Academic Article GET IT
Times cited: 14
Authors' reply. The British journal of psychiatry : the journal of mental science. 2015 Letter GET IT
Measuring adherence to medication in schizophrenia: the relationship between attitudes toward drug therapy and plasma levels of new-generation antipsychotics. The international journal of neuropsychopharmacology. 2014 Academic Article GET IT
Times cited: 7
Antipsychotic medications for schizophrenia. JAMA. 2014 Letter GET IT
Times cited: 3
Effects of aripiprazole once-monthly on domains of personal and social performance: results from 2 multicenter, randomized, double-blind studies. Schizophrenia research. 2014 Academic Article GET IT
Times cited: 27
Extrapyramidal symptoms during treatment of first schizophrenia episode: results from EUFEST. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2014 Academic Article GET IT
Times cited: 27
New therapeutic approaches for treatment-resistant schizophrenia: a look to the future. Journal of psychiatric research. 2014 Review GET IT
Times cited: 48
Risk of violence of inpatients with severe mental illness--do patients with schizophrenia pose harm to others?. Psychiatry research. 2014 Academic Article GET IT
Times cited: 16
Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. The British journal of psychiatry : the journal of mental science. 2014 Academic Article GET IT
Times cited: 144
Successful Electroconvulsive Therapy in a Clozapine-Refractory Schizophrenia Patient with Meningioma. 2014 GET IT
Sibutramine in the treatment of antipsychotic-induced weight gain: a pilot study in patients with schizophrenia. International clinical psychopharmacology. 2014 Academic Article GET IT
Times cited: 15
How antipsychotics impact the different dimensions of Schizophrenia: a test of competing hypotheses. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2014 Academic Article GET IT
Times cited: 14
Schizophrenia--time to commit to policy change. Schizophrenia bulletin. 2014 Academic Article GET IT
Times cited: 186
Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophrenia bulletin. 2014 Review GET IT
Times cited: 179
Completed and attempted suicides among 18,154 subjects with schizophrenia included in a large simple trial. The Journal of clinical psychiatry. 2014 Academic Article GET IT
Times cited: 50
SMARTS (Systematic Monitoring of Adverse events Related to TreatmentS): The development of a pragmatic patient-completed checklist to assess antipsychotic drug side effects. Therapeutic advances in psychopharmacology. 2014 Academic Article GET IT
Times cited: 39
Facial affect recognition in symptomatically remitted patients with schizophrenia and bipolar disorder. Schizophrenia research. 2013 Academic Article GET IT
Times cited: 45
Stratified medicine for mental disorders. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2013 Review GET IT
Times cited: 168
Adherence/compliance: a multifaceted challenge. World psychiatry : official journal of the World Psychiatric Association (WPA). 2013 Academic Article GET IT
Times cited: 3
Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. Schizophrenia research. 2013 Review GET IT
Times cited: 52
Polypharmacy: the good, the bad and the ugly. The international journal of neuropsychopharmacology. 2013 Editorial Article GET IT
Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective. CNS drugs. 2013 Review GET IT
Times cited: 59
Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophrenia research. 2013 Academic Article GET IT
Times cited: 100
Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. International clinical psychopharmacology. 2013 Academic Article GET IT
Times cited: 39
Treatment of psychotic and behavioral symptoms with clozapine, aripiprazole, and reboxetine in a patient with Huntington's disease. 2013 GET IT
Times cited: 11
Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis. Psychological medicine. 2013 Academic Article GET IT
Times cited: 89
Insight and hostility as predictors and correlates of nonadherence in the European First Episode Schizophrenia Trial. Journal of clinical psychopharmacology. 2013 Letter GET IT
Times cited: 20
Comorbid substance abuse in first-episode schizophrenia: effects on cognition and psychopathology in the EUFEST study. Schizophrenia research. 2013 Academic Article GET IT
Times cited: 51
Alternative pharmacologic targets for the treatment of schizophrenia: results from phase I and II trials. Current opinion in psychiatry. 2013 Review GET IT
Times cited: 22
Encouraging a new generation of researchers in a time of limited resources. Current opinion in psychiatry. 2013 Editorial Article GET IT
Are original, branded psychotropics and generic medications interchangeable?. Acta psychiatrica Scandinavica. 2013 Editorial Article GET IT
Times cited: 1
[Not Available]. Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater. 2013 Article GET IT
Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial. The international journal of neuropsychopharmacology. 2012 Academic Article GET IT
Times cited: 80
Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Archives of general psychiatry. 2012 Academic Article GET IT
Times cited: 163
Paliperidone: a review of clinical trial data and clinical implications. Clinical drug investigation. 2012 Review GET IT
Times cited: 21
Cognitive remediation therapy during treatment for alcohol dependence. Journal of studies on alcohol and drugs. 2012 Academic Article GET IT
Times cited: 120
Should a 'psychosis risk syndrome' be a separate diagnosis in DSM-5?. Current opinion in psychiatry. 2012 Editorial Article GET IT
Times cited: 3
Management of a risperidone-induced tardive Pisa syndrome: a case report. Journal of clinical psychopharmacology. 2012 Letter GET IT
Times cited: 10
Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2012 Academic Article GET IT
Times cited: 133
Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. The international journal of neuropsychopharmacology. 2012 Review GET IT
Times cited: 128
Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. The Journal of clinical psychiatry. 2012 Academic Article GET IT
Times cited: 192
Interpreting treatment trials in schizophrenia patients: lessons learned from EUFEST. Schizophrenia research. 2012 Academic Article GET IT
Times cited: 4
Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?. The international journal of neuropsychopharmacology. 2012 Review GET IT
Times cited: 71
Managing the prodrome of schizophrenia. Handbook of experimental pharmacology. 2012 Review GET IT
Times cited: 6
[Not Available]. Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater. 2012 Editorial Article GET IT
[Not Available]. Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater. 2012 Editorial Article GET IT
Combined clozapine and electroconvulsive therapy in clozapine-resistant schizophrenia: clinical and cognitive outcomes. The journal of ECT. 2011 Letter GET IT
Times cited: 12
The interrelation of needs and quality of life in first-episode schizophrenia. European archives of psychiatry and clinical neuroscience. 2011 Academic Article GET IT
Times cited: 16
A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. The international journal of neuropsychopharmacology. 2011 Academic Article GET IT
Times cited: 92
Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST). The Journal of clinical psychiatry. 2011 Academic Article GET IT
Times cited: 48
Sexual dysfunction in first-episode schizophrenia patients: results from European First Episode Schizophrenia Trial. Journal of clinical psychopharmacology. 2011 Academic Article GET IT
Times cited: 103
Emerging drugs for schizophrenia. Expert opinion on emerging drugs. 2011 Review GET IT
Times cited: 20
Poor health behaviour and reduced quality of life of people treated with psychotropic drugs. Human psychopharmacology. 2011 Academic Article GET IT
Times cited: 22
Technology-driven science: will it advance treatment of schizophrenia going into the second decade of the 21st century?. Current opinion in psychiatry. 2011 Academic Article GET IT
Prolactin levels and sexual adverse effects in patients with schizophrenia during antipsychotic treatment. Journal of clinical psychopharmacology. 2010 Academic Article GET IT
Times cited: 38
Insight: demographic differences and associations with one-year outcome in schizophrenia and schizoaffective disorder. Clinical schizophrenia & related psychoses. 2010 Academic Article GET IT
Times cited: 35
Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. The international journal of neuropsychopharmacology. 2010 Academic Article GET IT
Times cited: 174
Attitudes of patients with schizophrenia and depression towards psychiatric research. Psychiatry research. 2010 Academic Article GET IT
Times cited: 10
Antipsychotic drug treatment in first-episode psychosis: should patients be switched to a different antipsychotic drug after 2, 4, or 6 weeks of nonresponse?. Journal of clinical psychopharmacology. 2010 Academic Article GET IT
Times cited: 52
Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST). European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2010 Academic Article GET IT
Times cited: 69
Schizophrenia treatment: entering a new decade. Current opinion in psychiatry. 2010 Editorial Article GET IT
Times cited: 1
Attitudes of patients with schizophrenia and depression to psychiatric research: a study in seven European countries. Social psychiatry and psychiatric epidemiology. 2010 Academic Article GET IT
Times cited: 16
[Neurocognition and social cognition in patients with schizophrenia or mood disorders]. Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater. 2010 Review GET IT
Times cited: 15
Second-generation antipsychotic long-acting injections: systematic review. The British journal of psychiatry. Supplement. 2009 Academic Article GET IT
Times cited: 64
Generalizability of the results of efficacy trials in first-episode schizophrenia: comparisons between subgroups of participants of the European First Episode Schizophrenia Trial (EUFEST). The Journal of clinical psychiatry. 2009 Academic Article GET IT
Times cited: 20
Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophrenia research. 2009 Academic Article GET IT
Times cited: 103
Experimental antipsychotics and metabolic adverse effects--findings from clinical trials. Current opinion in investigational drugs (London, England : 2000). 2009 Review GET IT
Times cited: 8
Factors influencing the choice of new generation antipsychotic medication in the treatment of patients with schizophrenia. Schizophrenia research. 2009 Academic Article GET IT
Times cited: 23
Antipsychotics in the early stage of development. Current opinion in psychiatry. 2009 Review GET IT
Times cited: 16
Tolerability of antipsychotics: recent controversies and future management. The Journal of clinical psychiatry. 2009 Academic Article GET IT
Times cited: 4
Has there been progress in schizophrenia research and treatment for all peoples during 2008? Existing disparities in mental healthcare and research?. Current opinion in psychiatry. 2009 Editorial Article GET IT
Effectiveness as an outcome measure for treatment trials in psychiatry. World psychiatry : official journal of the World Psychiatric Association (WPA). 2009 Academic Article GET IT
Times cited: 24
Is second-generation antipsychotic-induced hyperprolactinemia due to biologically active prolactin or to biologically inactive macroprolactin? Results from a prospective study. The Journal of clinical psychiatry. 2009 Letter GET IT
Times cited: 9
Low bone mineral density and impaired bone metabolism in young alcoholic patients without liver cirrhosis: a cross-sectional study. Alcoholism, clinical and experimental research. 2008 Academic Article GET IT
Times cited: 90
A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biological psychiatry. 2008 Academic Article GET IT
Times cited: 89
Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. The Journal of clinical psychiatry. 2008 Conference Paper GET IT
Times cited: 293

more ...

less ...

Background

education and training

M.D., Innsbruck Medical University (Austria) 78

Contact

full name

Walter Fleischhacker

VIVO Weill Cornell Medical College

Walter Fleischhacker Clinical Professor of Psychiatry (Courtesy)

Publications

selected publications

Background

education and training

Contact

full name